A+ Science Invest AB (publ.) Interim Report, 1st January - 30th June 2001
A+ Science Invest AB (publ.) Interim Report, 1st January - 30th June 2001 A+ Science Invest AB (publ.) was formed in October 1997 and a multitude of projects and project ideas, mainly from Göteborg University, have been evaluated, acquired, considerably refined, further documented and developed by A+, successfully creating an increased value. During spring A+ has focused on reaching a point of exit in several projects, some have been further developed, and new projects have been evaluated for the portfolio. The activities of the period can be summarised as follows: · A licence agreement on the development of a novel treatment for Helicobacter pylori was signed with Carbion OY · The future development of novel medications in the area of dyspepsia and inflammatory bowel syndrome was transferred to an associated company, Pharmacore AB · Projects regarding cell manipulation and measurements will be transferred to Cellectricon AB · Stem cell activities will be transferred to the newly formed Cell Therapeutics (Scandinavia) · In vitro and animal studies in cancer and diabetes projects have been initiated · Clinical studies in sciatica, obstructive sleep apnoea and diabetes projects are ongoing · Investments in projects for the period amounted to 11.2 MSEK (8.4 MSEK) · The annual shareholders meeting authorised that the Board of Directors might increase the number of shares by a new stock issue of 15.000.000 shares. This Interim Report will be available on A+ Science Invest´s website www.a-plusscience.com under the heading "Financial Information". For more information, please contact: Boo Edgar, Managing Director, Phone +46 31 778 2131, Cellphone +46 708 888 427 Anders Sjögren, Finance Director, Phone +46 31 778 2132, Cellphone +46 708 888 421 A+ Science Invest AB (publ.) identifies, evaluates, acquires, finances, develops and commercialises patentable and marketable inventions arising from medical and scientific research, with a focus on healthcare. The project portfolio comprises some thirty projects in medicine and biotechnology. Major owners are the National Pension Insurance Fund, Sixth Fund Board, The Holding Company at Göteborg University, Investor Investments Novare Limited, Biofund, and Optiomi OY. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/09/05/20010904BIT01000/bit0001.pdf Full Report